Tirzepatide TFA (LY3298176 TFA, GIP and GLP-1 receptor agonist)-Therapeutic peptides drug benchmark for in-vivo/in-vitro study
Cat No.: GMP-Bios-peptide-001 Product Name: Tirzepatide TFA Structural formula:Tirzepatide TFA, the trifluoroacetic acid salt form of Tirzepatide. Tirzepatide, a new glucose-lowering therapy for diabetes, is called a “dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist”. Drug company Lilly released important results showing that this new therapy may be extremely effective for people with type 2 diabetes. Across three clinical trials, tirzepatide reduced A1C by an average of 2.5 percentage points and led to a weight loss of about 25 pounds.
Order information
Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
---|---|---|---|---|
GMP-Bios-peptide-001-5mg | 5mg | 780 | ||
GMP-Bios-peptide-001-25mg | 25mg | 1950 | ||
GMP-Bios-peptide-001-50mg | 50mg | 2925 | GMP-Bios-peptide-001-100mg | 100mg | 3900 |
GMP-Bios-peptide-001-500mg | 500mg | 7800 | ||
GMP-Bios-peptide-001-xmg | ≥500mg | Inquiry | ||
Shipping Cost: | 760.00 | |||
Total: | ||||
Description
Product Name | Tirzepatide TFA |
Brand name | NA (also known as LY3298176 TFA) |
CAS No. | 2023788-19-2 |
Formula | C227H349F3N48O70 |
Biological Activity | Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. |
Purity | Purity: ≥98% (HPLC) |
Application | Therapeutic peptides drug benchmark or raw material for peptide drugs or peptide conjugation drugs discovery and development. |
Predicted Molecular Mass | 4927.47 |
Formulation | Powder |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
- GENEMEDI
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
<